Enfortumab vedotin induces immunogenic cell death and shows enhanced preclinical antitumor activity when combined with a PD-1 inhibitor
Vaccination with enfortumab vedotin-treated tumor cells results in protection against tumor rechallenge in mice, consistent with antitumor immunity, and MMAE-mediated ICD induction modulates the tumor microenvironment in a complementary manner to immune checkpoint inhibition.